Vaxcyte (PCVX) Competitors

Vaxcyte (NASDAQ:PCVX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Do institutionals and insiders hold more shares of PCVX or GMAB?

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is PCVX or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to Vaxcyte's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-16.85%	-15.92%
Genmab A/S	37.53%	21.03%	16.98%

Which has preferable valuation and earnings, PCVX or GMAB?

Genmab A/S has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$463.93M	-$4.11	-7.30
Genmab A/S	$3.12B	4.49	$1.14B	$1.99	10.99

Which has more volatility & risk, PCVX or GMAB?

Vaxcyte has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Do analysts recommend PCVX or GMAB?

Vaxcyte currently has a consensus target price of $136.50, suggesting a potential upside of 355.00%. Genmab A/S has a consensus target price of $37.80, suggesting a potential upside of 72.84%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vaxcyte is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Does the media refer more to PCVX or GMAB?

In the previous week, Genmab A/S had 6 more articles in the media than Vaxcyte. MarketBeat recorded 25 mentions for Genmab A/S and 19 mentions for Vaxcyte. Genmab A/S's average media sentiment score of 1.09 beat Vaxcyte's score of 0.09 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Genmab A/S	11 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Vaxcyte on 9 of the 15 factors compared between the two stocks.